D
David Findlay
Researcher at British Society for Antimicrobial Chemotherapy
Publications - 4
Citations - 438
David Findlay is an academic researcher from British Society for Antimicrobial Chemotherapy. The author has contributed to research in topics: Cost–benefit analysis & Return on investment. The author has an hindex of 4, co-authored 4 publications receiving 399 citations. Previous affiliations of David Findlay include University of Nottingham.
Papers
More filters
Journal ArticleDOI
Discovery research: the scientific challenge of finding new antibiotics
David M. Livermore,Martin J. Blaser,Otto Carrs,Gail H. Cassell,Neil O. Fishman,Robert Guidos,Stuart B. Levy,John H. Powers,Ragnar Norrby,Glenn S. Tillotson,Rick Davies,Steven J. Projan,Michael J. Dawson,Dominique L Monnet,Marcus Keogh-Brown,Kieran Hand,Sarah Garner,David Findlay,Chantal M. Morel,Richard Wise,Richard Bax,Frances Burke,Ian Chopra,Lloyd George Czaplewski,Roger Finch,Livermore David,Laura J. V. Piddock,Tony White +27 more
TL;DR: Although a raft of start-up companies are now finding new antibiotic compounds, their development through Phase III depends on financial commitments from large pharmaceutical companies, where the discouraging regulatory environment and the poor likely return on investment remain paramount issues.
Journal ArticleDOI
The urgent need for new antibacterial agents
Richard Wise,Martin Blaser,Otto Carrs,Gail Cassell,Neil Fishman,Robert Guidos,Stuart Levy,John H. Powers,Ragnar Norrby,Glenn S. Tillotson,Rick Davies,Steven J. Projan,Michael J. Dawson,Dominique Monnet,Marcus Keogh-Brown,Kieran Hand,Sarah Garner,David Findlay,Chantal M. Morel,Richard Bax,Frances Burke,Ian Chopra,Lloyd George Czaplewski,Roger Finch,David Livermore,Laura J. V. Piddock,Tony White +26 more
TL;DR: Rather than restate the concerns surrounding antimicrobial resistance, its surveillance and how it might be contained, the BSAC adopted a different approach, focusing on the barriers to discovery and development of new technologies that might combat resistance (including new antimicrobial agents) and how these might be overcome.
Journal ArticleDOI
Effective antibacterials: at what cost? The economics of antibacterial resistance and its control
Anthony R. White,Martin J. Blaser,Otto Carrs,Gail H. Cassell,Neil O. Fishman,Robert Guidos,Stuart B. Levy,John H. Powers,Ragnar Norrby,Glenn S. Tillotson,Rick Davies,Steven J. Projan,Michael J. Dawson,Dominique L Monnet,Marcus Keogh-Brown,Kieran Hand,Sarah Garner,David Findlay,Chantal M. Morel,Richard Wise,Richard Bax,Frances Burke,Ian Chopra,Lloyd George Czaplewski,Roger Finch,David M. Livermore,Laura J. V. Piddock,Tony White +27 more
TL;DR: The development and economic model of antibacterial use needs to be rebuilt based on this value through dialogue with the various stakeholders, including the pharmaceutical industry, and alternative incentives from 'push' to 'pull' and funding models, such as public/private partnerships, agreed.
Journal ArticleDOI
Regulatory opportunities to encourage technology solutions to antibacterial drug resistance
Roger Finch,Martin J. Blaser,Otto Carrs,Gail Cassell,Neil Fishman,Robert Guidos,Stuart Levy,John H. Powers,Ragnar Norrby,Glenn Tillotson,Rick Davies,Steven J. Projan,Michael J. Dawson,Dominique Monnet,Marcus Keogh-Brown,Kieran Hand,Sarah Garner,David Findlay,Chantal M. Morel,Richard Wise,Richard Bax,Frances Burke,Ian Chopra,Lloyd Czaplewski,David M. Livermore,Laura J. V. Piddock,Tony White +26 more
TL;DR: The 'Urgent Need' Working Party to address the regeneration of antibacterial drug discovery and development identified a number of issues, including increased application of pharmacokinetic/pharmacodynamic principles to expedite drug development; the need to prioritize licensing of drugs active in life-threatening infections; and expansion of the use of surrogate markers and rapid point of care diagnostics to facilitate drug development.